Ryan Collins

T|G客服 自助网站

[Ryan Collins @Domm_washington]

Be a gift to the world around you.
海外获客🪐主人的任务🌱海外获客🌺互推助手🎌数字货币🍁外✒facebook推广
推特矩阵管理、营销自动化、内容运营推特账号上门呼和浩特
推特矩阵系统、Twitter矩阵系统、X矩阵系统海外获客🌺互推助手🎌数字货币🍁围574006软件获客、海外推广、流量增长
推特脚本

[Ryan Collins @Domm_washington]

@danadams_46 Not ready to call the bottom, but the setup looks better than it did a few days ago.

[Ryan Collins @Domm_washington]

@danadams_46 I still think AI demand is intact. The short-term problem is investors cutting risk everywhere.

[Ryan Collins @Domm_washington]

@danadams_46 SK Hynix stabilizing would definitely help the whole memory group breathe again.

[Ryan Collins @Domm_washington]

@demonbabies Robotic surgery feels like one of the clearest real-world AI use cases.

[Ryan Collins @Domm_washington]

@demonbabies Keeping some $MU while looking beyond semis makes sense here.

[Ryan Collins @Domm_washington]

@danikissel8 Sentiment changed much faster than the fundamentals today. The next few capex updates should tell us whether this was fear or a real shift in demand.

[Ryan Collins @Domm_washington]

CELC’s real debate begins after $100
QQQ was strong and biotech followed, but CELC did not turn into a clean breakout.

I am watching relative strength here: the FDA catalyst is alive and money has not left, yet above $100 the stock is clearly testing support.
Setup or priced in?

[Ryan Collins @Domm_washington]

Biotech moves differently from mega-cap tech.

For $CELC, the market is judging a clinical story: VIKTORIA-1 data, FDA timing, and whether risk appetite survives a short holiday week.

I like the setup, but small-cap biotech never gives free comfort.

$CELC #Biotech #FDA #Stocks

[Ryan Collins @Domm_washington]

This is the $CELC setup I’m watching.

July 17 is the real catalyst, but price action matters before the decision. Holding near $100 tells me buyers are still positioning for the FDA trade, not just chasing biotech noise.

[Casey | Trade Tracs @CaseyVSilver]

$CELC is a name every biotech trader needs on their radar right now 👀

July 17 FDA decision date for gedatolisib is the catalyst — binary event approaching fast. Meanwhile, management is already expanding the VIKTORIA-2 trial, signaling confidence in the program ahead of the ruling.

Approval = potential re-rating. Rejection = gap down risk. Classic binary setup. No live data in hand, but this is the kind of name that moves 50%+ on readthrough.

Adding to watchlist ahead of July 17. Size accordingly — this isn't a set-and-forget hold into the decision ⚠️

#Biotech #FDAcatalyst #CELC

[Ryan Collins @Domm_washington]

@WallStSai Biotech attention is definitely heating up again. For $CELC, I’m less focused on M&A rumors and more focused on the FDA clock. Holding near $100 before July 17 keeps the event trade alive.

[Ryan Collins @Domm_washington]

@ripster47 That $100 area is the key for $CELC now. If buyers keep defending it before July 17, the FDA trade stays alive. This move looks like positioning, not random biotech noise.

[Ryan Collins @Domm_washington]

$CELC above 100 is exactly what shorts hate before the FDA clock restarts.

The stock tested 101, held most gains, and XBI stayed firm.
I see buyers positioning ahead of July 17; a stable tape around 100 gives event traders room to add now.

Support this time?

#CELC #FDA

[Ryan Collins @Domm_washington]

$CELC’s $100 level has become the emotional pressure point before the FDA catalyst.

The breakout faded, showing active supply, but buyers still stepped in near the key zone.

My view: July 17 turns this level into an event-positioning fight.

Launch pad or ceiling?

$CELC #FDA

[Ryan Collins @Domm_washington]

Everyone is still focused on $CELC's ASCO pullback.

I think they're watching the wrong catalyst.

The July 17 FDA decision matters more. Priority Review is already in place. I believe approval would reprice CELC.

What happens if FDA says yes?

#FDA #Biotech #Oncology

[Ryan Collins @Domm_washington]

Markets are closed, but $CELC remains on my watchlist.

Precision oncology continues attracting capital, and recent optimism has pushed more investors to notice CELC.

The opportunity is obvious. The uncertainty remains.

#CELC #Biotech #Cancer #PrecisionMedicine

[Ryan Collins @Domm_washington]

Everyone talks about CELC's recent pullback.

Few people talk about what happens if Gedatolisib gains approval and reaches commercial markets.

Biotech fortunes can change fast when the market starts pricing future revenue instead of trial results.

#CELC #Biotech #GrowthStocks

[Ryan Collins @Domm_washington]

Most people focus on the latest trial result.

I'm paying attention to what comes next.

When a biotech moves from clinical validation toward potential commercialization, the conversation changes completely.

#CELC #Biotech #HealthcareStocks

[Ryan Collins @Domm_washington]

CELC is being misread as a “post-dilution loser.”

But the Phase 3 dataset still shows clinically meaningful separation vs standard care — that part didn’t change.

Early positioning usually happens during this disconnect phase.

#CELC #Biotech #MarketInefficiency #StockSetup

[Ryan Collins @Domm_washington]

#CELC today is not trending—it’s holding a tight range around recent levels.

That usually means positioning is being built quietly, not aggressively.

I watch these compression phases closely.

If you want access, contact me.

#Biotech #CELC #Stocks